Dname-iT
2 known investors
Find your way into Dname-iT
Sign up to see every warm intro you have to Dname-iT
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Dname-iT team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
DName-iT, a KU Leuven spin-off, has developed a DNA-based barcode labelling technology and software platform (DNames™) that tracks and identifies next-generation sequencing (NGS) specimens to detect handling errors. It serves clinical laboratories and the liquid biopsy, clinical trials and NGS markets, with an initial focus on non-invasive prenatal testing and later cancer therapy selection.
Founders & leadership
HC
Harry CuppensFounder & CSO
Investors · 2
EMV Capitallisted by EMV CapitalLondon
How we know: EMV Capital's portfolio page · funding news · dnameit.com · Not right? Tell us
Also in the syndicate · 1
Gemma Frisius Fund
In the news
Frequently asked questions
- What does Dname-iT do?
- DName-iT, a KU Leuven spin-off, has developed a DNA-based barcode labelling technology and software platform (DNames™) that tracks and identifies next-generation sequencing (NGS) specimens to detect handling errors. It serves clinical laboratories and the liquid biopsy, clinical trials and NGS markets, with an initial focus on non-invasive prenatal testing and later cancer therapy selection.
- Who are Dname-iT's investors?
- Dname-iT's investors include EMV Capital.
